Chapter 4
Epidemiology and Prevention
Benjamin Cowie,
Stephen A. Locarnini,
Benjamin Cowie
Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorStephen A. Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorBenjamin Cowie,
Stephen A. Locarnini,
Benjamin Cowie
Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorStephen A. Locarnini
Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorBook Editor(s):Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci,
Anna S.F. Lok MD,
Stephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath,
Arie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci,
Howard C. Thomas BSc, PhD, FRCP, FRCPath, FMedSci
Emeritus Professor of Hepatology, Department of Medicine, Imperial College London, London, UK
Search for more papers by this authorAnna S.F. Lok MD
Alice Lohrman Andrews Research Professor in Hepatology, Director of Clinical Hepatology, Professor of Internal Medicine, Associate Chair for Clinical Research, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA
Search for more papers by this authorStephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPath
Head, Research & Molecular Development, Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC, Australia
Search for more papers by this authorArie J. Zuckerman MD, DSc, FRCP, FRCPath, FMedSci
Emeritus Professor of Medical Microbiology, Formerly Principal and Dean, Royal Free Hospital School of Medicine
Search for more papers by this authorFirst published: 26 July 2013
Summary
Hepatitis A infects millions of humans annually, with the epidemiological patterns of infection showing distinct differences related to access to adequate sanitation and hygiene. These differences influence age at infection, which in turn largely determines the clinical course of infection. In addition to improving access to sanitation and clean drinking water, active and passive vaccination play important roles in the prevention of hepatitis A infection.
References
- Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010; 28: 6653–6657 [Epub 2010/08/21].
- Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004; 132: 1005–1022 [Epub 2005/01/08].
- Mohd Hanafiah K, Jacobsen KH, Wiersma ST. Challenges to mapping the health risk of hepatitis A virus infection. Int J Health Geograph 2011; 10: 57 [Epub 2011/10/20].
- Heywood AE, Newall AT, Gao Z, et al. Changes in seroprevalence to hepatitis A in Victoria, Australia: a comparison of three time points. Vaccine 2012; 30: 6020–6026 [Epub 2012/08/08].
-
Fangcheng Z,
Xuanyi W,
Mingding C, et al.
Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China.
Hepat Monthly
2012;
12:
100–105 [Epub 2012/04/18].
10.5812/hepatmon.4907 Google Scholar
- Daniels D, Grytdal S, Wasley A. Surveillance for acute viral hepatitis – United States, 2007. MMWR Surveill Summ 2009; 58: 1–27 [Epub 2009/05/30].
- Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55(RR-7): 1–23 [Epub 2006/05/19].
- Craig AS, Schaffner W. Prevention of hepatitis A with the hepatitis A vaccine. N Engl J Med 2004; 350: 476–481 [Epub 2004/01/30].
- Ott JJ, Irving G, Wiersma ST. Long-term protective effects of hepatitis A vaccines: a systematic review. Vaccine 2012; 31: 3–11 [Epub 2012/05/23].
- Victor JC, Monto AS, Surdina TY, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med 2007; 357: 1685–1694 [Epub 2007/10/20].
- Polish LB, Robertson BH, Khanna B, et al. Excretion of hepatitis A virus (HAV) in adults: comparison of immunologic and molecular detection methods and relationship between HAV positivity and infectivity in tamarins. J Clin Microbiol 1999; 37: 3615–3617 [Epub 1999/10/19].
- Koff RS. Seroepidemiology of hepatitis A in the United States. J Infect Dis 1995; 171(Suppl 1): S19–S23 [Epub 1995/03/01].
- Shapiro CN, Hadler SC. Hepatitis A and hepatitis B virus infections in day-care settings. Pediatr Ann 1991; 20: 435–441 [Epub 1991/08/01].
- Goodman RA, Carder CC, Allen JR, Orenstein WA, Finton RJ. Nosocomial hepatitis A transmission by an adult patient with diarrhea. Am J Med 1982; 73: 220–226 [Epub 1982/08/01].
- Control CfD. Hepatitis A among homosexual men – United States, Canada and Australia. MMWR 1992; 41: 161–164.
- Stewart T, Crofts N. An outbreak of hepatitis A among homosexual men in Melbourne. Med J Austral 1993; 158: 519–521 [Epub 1993/04/19].
- Henning KJ, Bell E, Braun J, Barker ND. A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med 1995; 99: 132–136 [Epub 1995/08/01].
- Cotter SM, Sansom S, Long T, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003; 187: 1235–1240 [Epub 2003/04/16].
- Hu MD. Isolation of HAV and HAV RNA from hairy clams in Qidong region by using cell culture and RNA hybridization technique. Shanghai Med J 1989; 12: 72–73.
- Koff RS, Sear HS. Internal temperature of steamed clams. N Engl J Med 1967; 276: 737–739 [Epub 1967/03/30].
- Enriquez R, Frosner GG, Hochstein-Mintzel V, Riedemann S, Reinhardt G. Accumulation and persistence of hepatitis A virus in mussels. J Med Virol 1992; 37: 174–179 [Epub 1992/07/01].
- Wolfe MS. Hepatitis A and the American traveler. J Infect Dis 1995; 171(Suppl 1): S29–S32 [Epub 1995/03/01].
- Purcell RH, Wong DC, Shapiro M. Relative infectivity of hepatitis A virus by the oral and intravenous routes in 2 species of nonhuman primates. J Infect Dis 2002; 185: 1668–1671 [Epub 2002/05/23].
- Fujiwara K, Yokosuka O, Ehata T, et al. Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology 1997; 26: 1634–1639 [Epub 1997/12/16].
- Bower WA, Nainan OV, Han X, Margolis HS. Duration of viremia in hepatitis A virus infection. J Infect Dis 2000; 182: 12–17 [Epub 2000/07/07].
- Sirchia G, Giovanetti AM, Parravicini A, et al. Prospective evaluation of posttransfusion hepatitis. Transfusion 1991; 31: 299–302 [Epub 1991/05/01].
- Shouval D, Gerlich W. Clotting factors and hepatitis A. Lancet 1990; 340: 1465–1466.
- Control CfD. Hepatitis A among drug abusers. MMWR 1988; 37: 297–305.
- Prevention CfDCa. Viral Hepatitis Surveillance Program 1993. Hepat Surveil Rep 1996; 56(21–32).
- Scheutz F, Skinhoj P, Mark I. Viral hepatitis among parenteral drug addicts attending a Danish addiction clinic. Scand J Infect Dis 1983; 15: 139–143 [Epub 1983/01/01].
- Tanaka I, Shima M, Kubota Y, Takahashi Y, Kawamata O, Yoshioka A. Vertical transmission of hepatitis A virus. Lancet 1995; 345: 397 [Epub 1995/02/11].
- Gust I. The epidemiology of viral hepatitis. In: GN Vyas, JL Dienstag, JH H , editors. Viral hepatitis and liver disease. Orlando, FL: Grime & Stratton; 1984; p. 415–421.
- Gust ID, Lehmann NI, Dimitrakakis M. A seroepidemiologic study of infection with HAV and HBV in five Pacific Islands. Am J Epidemiol 1979; 110: 237–242 [Epub 1979/09/01].
- Gay NJ, Morgan-Capner P, Wright J, Farrington CP, Miller E. Age-specific antibody prevalence to hepatitis A in England: implications for disease control. Epidemiol Infect 1994; 113: 113–120 [Epub 1994/08/01].
- Gust ID, Lehmann NI, Lucas CR. Relationship between prevalence of antibody to hepatitis A antigen and age: a cohort effect? J Infect Dis 1978; 138: 425–426 [Epub 1978/09/01].
- Frosner G, Willers H, Muller R, Schenzle D, Deinhardt F, Hopken W. Decrease in incidence of hepatitis A infections in Germany. Infection 1978; 6: 259–260 [Epub 1978/01/01].
- Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992; 10: S63–S66 [Epub 1992/01/01].
- Skinhoj P, Mikkelsen F, Hollinger FB. Hepatitis A in Greenland: importance of specific antibody testing in epidemiologic surveillance. Am J Epidemiol 1977; 105: 140–147 [Epub 1977/02/01].
- Innis BL, Snitbhan R, Hoke CH, Munindhorn W, Laorakpongse T. The declining transmission of hepatitis A in Thailand. J Infect Dis 1991; 163: 989–995 [Epub 1991/05/01].
- Jansen RW, Siegl G, Lemon SM. Molecular epidemiology of human hepatitis A virus defined by an antigen-capture polymerase chain reaction method. Proc Nat Acad Sci USA 1990; 87: 2867–2871 [Epub 1990/04/01].
- Robertson BH, Jansen RW, Khanna B, et al. Genetic relatedness of hepatitis A virus strains recovered from different geographical regions. J Gen Virol 1992; 73: 1365–1377 [Epub 1992/06/01].
- Sanchez G, Pinto RM, Vanaclocha H, Bosch A. Molecular characterization of hepatitis A virus isolates from a transcontinental shellfish-borne outbreak. J Clin Microbiol 2002; 40: 4148–4155 [Epub 2002/11/01].
- Bell BP. Global epidemiology of hepatitis A: implications for control strategies. In: HS Margolis, MJ Alter, JT Liang, JL Dienstag, editors. Viral hepatitis and liver disease. London: International Medical Press; 2002; p. 359–365.
- Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004; 38: 705–715 [Epub 2004/02/27].
- Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 2004; 22: 4342–4350 [Epub 2004/10/12].
- Provost PJ, Hilleman MR. Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 1979; 160: 213–221 [Epub 1979/02/01].
- Binn LN, Bancroft WH, Lemon SM, et al. Preparation of a prototype inactivated hepatitis A virus vaccine from infected cell cultures. J Infect Dis 1986; 153: 749–756 [Epub 1986/04/01].
- Gust ID, Lehmann NI, Crowe S, McCrorie M, Locarnini SA, Lucas CR. The origin of the HM175 strain of hepatitis A virus. J Infect Dis 1985; 151: 365–367 [Epub 1985/02/01].
- Flehmig B, Heinricy U, Pfisterer M. Prospects for a hepatitis A virus vaccine. Prog Med Virol 1990; 37: 56–71 [Epub 1990/01/01].
- Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15: 1209–1213 [Epub 1997/08/01].
- Anderson DA, Ross BC. Morphogenesis of hepatitis A virus: isolation and characterization of subviral particles. J Virol 1990; 64: 5284–5289 [Epub 1990/11/01].
- Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001; 19: 4710–4719 [Epub 2001/09/06].
- Bryan JP, Henry CH, Hoffman AG, et al. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2000; 19: 743–750 [Epub 2000/12/15].
- Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 2003; 21: 3208–3211 [Epub 2003/06/14].
- Tilzey AJ, Palmer SJ, Barrow S, et al. Effect of hepatitis A vaccination schedules on immune response. Vaccine 1992; 10: S121–S123 [Epub 1992/01/01].
- Nothdurft HD, Dietrich M, Zuckerman JN, et al. A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 2002; 20: 1157–1162 [Epub 2002/01/23].
- Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003; 362: 1065–1071 [Epub 2003/10/03].
- Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004; 144: 327–332 [Epub 2004/03/06].
- Kemper CA, Haubrich R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003; 187: 1327–1331 [Epub 2003/04/16].
- Kallinowski B, Jilg W, Buchholz L, Stremmel W, Engler S. Immunogenicity of an accelerated vaccination regime with a combined hepatitis A/B vaccine in patients with chronic hepatitis C. Zeit Gastroenterol 2003; 41: 983–990 [Epub 2003/10/17].
- Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992; 327: 453–457 [Epub 1992/08/13].
- Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003; 22: 354–359 [Epub 2003/04/12].
- Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004; 72: 194–196 [Epub 2003/12/26].
- Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000; 19: 1045–1052 [Epub 2000/12/01].
- Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol 2001; 63: 1–7 [Epub 2000/12/29].
- Landry P, Tremblay S, Darioli R, Genton B. Inactivated hepatitis A vaccine booster given >/=24 months after the primary dose. Vaccine 2000; 19: 399–402 [Epub 2000/10/12].
- Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 2002; 20: 1699–1701 [Epub 2002/03/22].
- Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4–6 y after a single primary dose of an inactivated hepatitis A vaccine. Scand J Infect Dis 2002; 34: 110–111 [Epub 2002/04/04].
- Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994; 271: 1328–1334 [Epub 1994/05/04].
- Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J Infect Dis 2003; 188: 671–627 [Epub 2003/08/23].
- Sagliocca L, Amoroso P, Stroffolini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 1999; 353: 1136–1139 [Epub 1999/04/21].
- Update: prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007; 56: 1080–1084 [Epub 2007/10/20].
- McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med 1996; 150: 733–739 [Epub 1996/07/01].
- Bialek SR, Thoroughman DA, Hu D, et al. Hepatitis A incidence and hepatitis A vaccination among American Indians and Alaska Natives, 1990–2001. Am J Public Health 2004; 94: 996–1001 [Epub 2004/07/14].
- Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA 2001; 286: 2968–2973 [Epub 2001/12/26].
- Lopalco PL, Salleras L, Barbuti S, et al. Hepatitis A and B in children and adolescents – what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2000; 19: 470–474 [Epub 2000/10/12].
- Centers for Disease Control and Prevention. Hepatitis surveillance report no. 58. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
- WHO position paper on hepatitis A vaccines – June 2012. Wkly Epidemiol Rec 2012; 87: 261–276 [Epub 2012/08/22].
- Franco E, Giambi C, Ialacci R, Coppola RC, Zanetti AR. Risk groups for hepatitis A virus infection. Vaccine 2003; 21: 2224–2233 [Epub 2003/05/15].
- Hutin YJ, Bell BP, Marshall KL, et al. Identifying target groups for a potential vaccination program during a hepatitis A communitywide outbreak. Am J Public Health 1999; 89: 918–921 [Epub 1999/06/08].
- Meltzer MI, Shapiro CN, Mast EE, Arcari C. The economics of vaccinating restaurant workers against hepatitis A. Vaccine 2001; 19: 2138–2145 [Epub 2001/03/03].
- Xu Z, Wang X, Li R, et al. [Immunogenicity and efficacy of two live attenuated hepatitis A vaccines (H(2) strains and LA-1 strains)]. Zhonghua yi xue za zhi 2002; 82: 678–681 [Epub 2002/07/23].
- Pierce PF, Cappello M, Bernard KW. Subclinical infection with hepatitis A in Peace Corps volunteers following immune globulin prophylaxis. Am J Trop Med Hyg 1990; 42: 465–469 [Epub 1990/05/01].
- Stokes J, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945; 127: 144–145.
- Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR 1986; 35: 231–233 [Epub 1986/04/11].
